Skip to content

End-of-life communication in nursing homes – Patient preferences and participation

Implementation of advance care planning in Norwegian nursing homes - a cluster randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN69571462
Enrollment
317
Registered
2017-03-14
Start date
2015-04-21
Completion date
Unknown
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Care Not Applicable Care

Interventions

Eight nursing home wards from eight nursing homes are pair-matchedusing the following data from a national survey/KOSTRA/the nursing home’s annual report: size of the municipality, size of the nursing

Sponsors

University of Oslo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Nursing home resident 2. Aged 70 years and over

Exclusion criteria

Exclusion criteria: 1. Under the age of 70 2. Do not understand or speak Norwegian 3. Severe psychiatric condition

Design outcomes

Primary

MeasureTime frame
Current primary outcome measures as of 15/02/2018: Number of patients with a documented conversation on end-of-life treatment assessed through electronic health record review at baseline and 12 months. Previous primary outcome measures: 1. Number of patients with a documented conversation on end-of-life treatment is assessed through electronic health record review at baseline and 12 months 2. Number of patients with a documented wish regarding life-prolonging treatment and hospitalisation assessed through electronic health record review at baseline and 12 months 3. Concordance between patient wishes and treatment given will be measured based on documentation of events assessed through electronic health record review at baseline and 12 months

Secondary

MeasureTime frame
Current secondary outcome measures as of 15/02/2018: Based on information in the patient's EHR the following secondary outcomes will be assessed (at baseline and at the end of the 12 month intervention period): 1. Patient's hopes and worries for the future 2. Patient’s wishes for a proxy, information to oneself and NOK, and patient wishes for participation in decision-making processes 3. Patient’s competence to consent assessed in relation to conversations on future life-prolonging treatment 4. Wishes regarding life-prolonging treatment and hospitalization 5. Patient’s own wishes regarding life-prolonging treatment and hospitalization are known 6. NOK's knowledge of the patients’ wishes regarding life-prolonging treatment and hospitalization 7. NOK's own opinion on life-prolonging treatment and hospitalization 8. Wishes regarding life-prolonging treatment and hospitalization being positive to treatment 9. Life-prolonging treatments and hospitalizations during the past 12 months 10. Life-prolonging treatments and hospitalizations decided not given during the past 12 months 11. Patient's competence to consent assessed during the past 12 months, when life-prolonging treatments and hospitalizations were given or decided not given 12. Concordance between patient wishes and treatment given will be measured based on documentation of events during the past 12 months. Previous secondary outcome measures: 1. Documentation of: patient's hopes and worries for the future, wishes for information to oneself and next of kin, wishes for participation in end-of-life decision-making 2. Decisions on end-of-life treatment and hospitalisation 3. Concordance between patient's previously expressed wishes and actual treatm

Countries

Norway

Contacts

Public ContactTrygve Johannes Lereim Sævareid
t.j.l.savareid@medisin.uio.no+47 22859204

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 2, 2026